Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Jim Cramer Says Chevron Is Doing 'Pretty Well,' Will Give This Pharma Giant 'A Chance'

Published 01/04/2024, 14:00
Updated 01/04/2024, 15:10
© Reuters.  Jim Cramer Says Chevron Is Doing 'Pretty Well,' Will Give This Pharma Giant 'A Chance'

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Core & Main, Inc. (NYSE: CNM) is "right at the heart of this infrastructure bull market I keep talking about because it does waste water. It is perfectly positioned…even though it’s just been a horse, it can go higher."

On March 19, Core & Main reported upbeat sales results for its fourth quarter. The company posted quarterly earnings of 34 cents per share, missing analysts’ estimates of 35 cents per share. The company’s quarterly sales came in at $1.44 billion, versus expectations of $1.43 billion, according to data from Benzinga Pro.

KLA Corporation (NASDAQ: KLAC) is a "very good" company, Cramer said.

On March 25, Stifel analyst Brian Chin reiterated KLA with a Buy and maintained a $685 price target.

Chevron Corporation (NYSE: CVX) has got a 4% yield and is doing "pretty well," Cramer said, "That’s Mike Wirth’s company, I’m not going to leave it here."

On March 18, Chevron’s Chevron New Energies inked a signed Memorandum Of Understanding with JX Nippon Oil & Gas Exploration Corporation to develop the CCS value chain.

"Let’s give Pfizer a chance. They’ve got this really good acquisition that I like of Seagen. Let’s give it some time here," Cramer said when asked about Pfizer Inc. (NYSE: PFE).

On March 22, Argus Research analyst David Toung downgraded Pfizer from Buy to Hold.

The "Mad Money" host said Leidos Holdings, Inc. (NYSE: LDOS) is a winner. "It’s a defense contractor that’s actually not struggling to get money out of Congress," he added.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

On March 27, B of A Securities analyst Mariana Perez maintained Leidos Holdings with a Buy and raised the price target from $125 to $145.

"People like these things, people like these bulk carriers right now," Cramer said when asked about SFL Corporation Ltd. (NYSE: SFL). "Do not overstay your welcome in this, it’s been a big run. But it’s going to go a little higher."

On Feb. 14, SFL posted better-than-expected results for its fourth quarter.

Price Action:

  • Shares of Core & Main gained 0.9% to close at $57.25 on Thursday.
  • Pfizer shares fell 0.1% to close at $27.75.
  • SFL shares gained 0.5% to settle at $13.18 on Thursday.
  • Leidos shares gained 0.4% to close at $131.09 during Thursday’s session.
  • KLA shares gained 0.2% to settle at $698.57.
  • Shares of Chevron gained 0.9% to close at $157.74 on Thursday.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.